비교리스트

 카트 문의
시장보고서
상품코드
1552541

RA(Regulatory Affairs) 시장 규모, 점유율 및 동향 분석 보고서 : 카테고리별, 기업 규모별, 유형별, 서비스별, 제품 단계별, 적응증별, 최종 용도별, 지역별, 부문별 예측(2024-2030년)

Regulatory Affairs Market Size, Share & Trends Analysis Report By Categories (Drugs, Biologics), By Company Size (Small, Large), By Type, By Services, By Product Stage, By Indication, By End Use, By Region, And Segment Forecasts, 2024 - 2030
발행일: | 리서치사: Grand View Research | 페이지 정보: 영문 120 Pages | 배송안내 : 2-10일 (영업일 기준)

    
    
    




※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

RA(Regulatory Affairs) 시장의 성장과 동향

Grand View Research, Inc.의 최신 보고서에 따르면, 세계 RA(Regulatory Affairs) 시장 규모는 2024-2030년간 8.2%의 연평균 복합 성장률(CAGR)로 확대되어 2030년에는 260억 달러에 달할 것으로 예상됩니다.

시장 성장에 기여할 것으로 예상되는 요인으로는 사업 활동과 지역에 따라 변화하는 규제 요건, 규제 당국의 신속한 승인에 따른 임상시험 및 의약품 승인 증가, 규제 당국용 소프트웨어의 기술 발전 등을 꼽을 수 있습니다. 또한, 개인 맞춤형 의약품의 발전, 기업의 핵심 비즈니스 활동에 집중해야 할 필요성 증가, 경제적 및 시장 경쟁 압력 등도 시장 성장에 기여하는 요인입니다.

제약회사와 규제 당국은 코로나19 감염에 대응하기 위해 필요한 백신과 의료 제품을 신속하게 개발하기 위해 협력하고 있습니다. 규제 당국은 임상시험 중 환자와 인력의 안전을 보장하고, 데이터의 무결성 및 적절한 실험실 운영을 유지하기 위해 여러 가지 예방 조치를 취하고 있습니다. 바이오시밀러, 희귀질환 치료제, 맞춤형 의약품, 동반진단, 적응증 시험 설계 등 시장 성장으로 인해 해당 분야의 규제당국의 전문성에 대한 수요가 증가할 것으로 예상됩니다. 기업들이 새로운 분야로 진출함에 따라 규제 준수에 대한 필요성이 높아지면서 약사 업무 전문성을 갖춘 전문 서비스 제공업체에 대한 수요가 증가하고 있습니다. 심렉트, 벡티빅스, 미르셀라, 키네레트와 같은 바이오의약품의 특허가 만료됨에 따라 바이오시밀러에 대한 수요와 개발이 증가하고 있으며, 이는 약사 서비스 수요에 기여하고 있습니다.

맞춤형 의료 시장에서 주도권을 잡기 위해 여러 기업이 제휴 및 신제품 개발에 적극적으로 나서고 있으며, 이는 약사 업무의 지원이 필요함을 보여줍니다. 예를 들어, 2020년 5월 Regeneron Pharmaceuticals, Inc.는 Colorado Center for Personalized Medicine과 제휴하여 맞춤형 의료 및 인간 유전학의 발전을 설계했습니다.

정규 업무 시장 보고서의 주요 내용

  • 2023년에는 아웃소싱 부문이 58.16%의 점유율을 차지하며 시장을 장악했습니다. 이 부문의 성장은 주로 제약 및 의료기기 회사가 사내에 없는 전문 지식과 자원을 활용할 수 있는 아웃소싱에 초점을 맞추기 시작했기 때문입니다.
  • 레귤러 라이팅 & 퍼블리싱 부문은 2023년 전 세계 매출의 36.41%를 차지하며 시장을 장악했습니다.
  • 의료기기 부문은 2023년 41.05%의 점유율을 차지하며 시장을 장악했습니다. 이 부문의 성장은 지속적인 기술 발전과 핵심 역량에 더 집중할 수 있도록 의료기기 업무의 아웃소싱에 초점을 맞추는 시장 참여자 증가 등의 요인에 기인합니다.
  • 종양학 부문은 2023년 32.77%의 점유율로 시장을 장악했습니다. 이 부문의 성장은 주로 효과적이고 안전한 치료 옵션이 필요한 암의 유병률 증가에 기인합니다.
  • 아시아태평양이 2023년 37.82%의 점유율을 차지하며 시장을 장악했습니다. 이 지역의 성장은 규제 강화, 임상시험 증가, 제약 회사 증가, 이 지역의 숙련된 인력 확보 등의 요인에 기인합니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 RA(Regulatory Affairs) 시장 변수, 동향, 범위

  • 시장 계통 전망
    • 상위 시장 전망
    • 관련/보조적인 시장 전망
  • 시장 역학
    • 시장 성장 촉진요인 분석
    • 시장 성장 억제요인 분석
  • RA(Regulatory Affairs) 시장 분석 툴
    • 업계 분석 - Porter의 Five Forces 분석
    • PESTEL 분석
    • COVID-19의 영향 분석

제4장 RA(Regulatory Affairs) 시장 : 서비스, 추정·동향 분석

  • 부문 대시보드
  • 세계의 RA(Regulatory Affairs) 시장 서비스 변동 분석
  • 세계의 RA(Regulatory Affairs) 시장 규모와 동향 분석, 서비스별, 2018-2030년
  • 규제 컨설팅
  • 법적 대리
  • 규제 문서 집필 및 출판
  • 제품 등록 및 임상시험 신청
  • 기타

제5장 RA(Regulatory Affairs) 시장 : 카테고리, 추정·동향 분석

  • 부문 대시보드
  • 세계 RA(Regulatory Affairs) 시장 카테고리 변동 분석
  • 세계의 RA(Regulatory Affairs) 시장 규모와 동향 분석, 카테고리별, 2018-2030년
  • 약제
  • 생물제제
  • 의료기기

제6장 RA(Regulatory Affairs) 시장 : 적응증, 추정·동향 분석

  • 부문 대시보드
  • 세계의 RA(Regulatory Affairs) 시장 적응증 변동 분석
  • 세계의 RA(Regulatory Affairs) 시장 규모와 동향 분석, 적응증별, 2018-2030년
  • 종양학
  • 신경학
  • 심장병학
  • 면역학
  • 기타

제7장 RA(Regulatory Affairs) 시장 : 제품 단계, 추정·동향 분석

  • 부문 대시보드
  • 세계의 RA(Regulatory Affairs) 시장 제품 단계 변동 분석
  • 세계의 RA(Regulatory Affairs) 시장 규모와 동향 분석, 제품 단계별, 2018-2030년
  • 전임상
  • 임상 연구
  • PMA

제8장 RA(Regulatory Affairs) 시장 : 유형, 추정·동향 분석

  • 부문 대시보드
  • 세계의 RA(Regulatory Affairs) 시장 유형 변동 분석
  • 세계의 RA(Regulatory Affairs) 시장 규모와 동향 분석, 유형별, 2018-2030년
  • 사내
  • 아웃소싱

제9장 RA(Regulatory Affairs) 시장 : 기업 규모, 추정·동향 분석

  • 부문 대시보드
  • 세계의 RA(Regulatory Affairs) 시장 기업 규모 변동 분석
  • 세계의 RA(Regulatory Affairs) 시장 규모와 동향 분석, 기업 규모별, 2018-2030년
  • 소
  • 중
  • 대

제10장 RA(Regulatory Affairs) 시장 : 최종 용도, 추정·동향 분석

  • 부문 대시보드
  • 세계의 RA(Regulatory Affairs) 시장 최종 용도 변동 분석
  • 세계의 RA(Regulatory Affairs) 시장 규모와 동향 분석, 최종 용도별, 2018-2030년
  • 의료기기 기업
  • 제약회사
  • 바이오테크놀러지 기업

제11장 RA(Regulatory Affairs) 시장 : 지역별, 추정·동향 분석

  • 지역별 시장 점유율 분석, 2023년 & 2030년
  • 지역별 시장 대시보드
  • 시장 규모, 예측 동향 분석, 2018-2030년
  • 북미
    • 북미 시장 추정·예측, 2018-2030년
    • 미국
    • 캐나다
    • 멕시코
  • 유럽
    • 유럽 시장 추정·예측, 2018-2030년
    • 영국
    • 독일
    • 프랑스
    • 이탈리아
    • 스페인
    • 덴마크
    • 노르웨이
    • 네덜란드
    • 스위스
    • 스웨덴
  • 아시아태평양
    • 아시아태평양 시장 추정·예측, 2018-2030년
    • 일본
    • 중국
    • 인도
    • 호주
    • 한국
    • 태국
    • 인도네시아
    • 말레이시아
    • 싱가포르
    • 대만
  • 라틴아메리카
    • 라틴아메리카 시장 추정·예측, 2018-2030년
    • 브라질
    • 아르헨티나
    • 콜롬비아
    • 칠레
  • 중동 및 아프리카
    • 중동 및 아프리카 시장 추정·예측, 2018-2030년
    • 남아프리카공화국
    • 사우디아라비아
    • 아랍에미리트(UAE)
    • 이집트
    • 이스라엘
    • 쿠웨이트

제12장 경쟁 구도

  • 기업/경쟁 분류
  • 전략 매핑
  • 기업 시장 현황 분석, 2023년
  • 기업 개요/상장기업
    • Accell Clinical Research, LLC
    • Genpact
    • Criterium, Inc.
    • ICON plc
    • iuvo BioScience, llc.
    • WuXi AppTec
    • Medpace
    • Charles River Laboratories
    • Laboratory Corporation of America Holdings
    • Parexel International(MA) Corporation
    • Freyr
    • PHARMALEX GMBH
    • SSI Strategy LLC
    • Pharmexon
    • Qvigilance
    • BlueReg
    • Cambridge Regulatory Services
    • VCLS
LSH 24.10.07

Regulatory Affairs Market Growth & Trends:

The global regulatory affairs market size is expected to reach USD 26.0 billion by 2030, expanding at a CAGR of 8.2% from 2024 to 2030, according to a new report by Grand View Research, Inc. The factors expected to contribute to the growth of this market include changing regulatory requirements based on business activities and geographies, an increase in clinical trials & drug approvals along with accelerated regulatory approval, and technological advancement in regulatory software. Also, the evolution of personalized medicines, the increasing need for companies to focus on core business activities, and economic and competitive pressures are other factors that are contributing to the growth of the market.

The pharmaceutical and regulatory agencies joined forces to rapidly develop vaccines and medical products required to fight against the COVID-19 infection. The regulatory authorities take numerous precautions to ensure patient and personnel safety during a clinical trial, as well as data integrity and good laboratory practices are maintained. Growth in markets for biosimilars, orphan drugs, personalized medicines, companion diagnostics, and adaptive trial designs is projected to boost the demand for regulatory specialization in these areas. As companies venture into newer fields, the growing need to comply with regulations is boosting the demand for specialized service providers with expertise in regulatory affairs. Patent expiration of biologics, such as Simulect, Vectibix, Mircera, and Kineret, is increasing the demand and development of biosimilars, thereby contributing to the demand for regulatory services.

Several companies are actively involved in collaborations and new product development to gain leadership in the personalized medicine market, indicating a need for supportive regulatory affairs. For instance, in May 2020, Regeneron Pharmaceuticals, Inc. collaborated with Colorado Center for Personalized Medicine to design advancements in personalized medicine and human genetics.

Regulatory Affairs Market Report Highlights:

  • The outsourcing segment dominated the market with a share of 58.16% in 2023. The segment's growth is mainly due to the growing focus of pharmaceutical and medical device companies on outsourcing their activities, which allows them to access specialized expertise and resources they may not have in-house.
  • The regulatory writing & publishing segment dominated the market, accounting for 36.41% of the global revenue in 2023.
  • The medical devices segment dominated the market with a share of 41.05% in 2023. The segment's growth can be attributed to factors such as constant technological advancements and the increasing focus of market players on outsourcing medical device activities so they can focus more on their core competencies.
  • The oncology segment dominated the market with a share of 32.77% in 2023. The growth of the segment is mainly due to the increasing prevalence of cancer, which requires effective and safe treatment options.
  • Asia Pacific dominated the market and accounted for a 37.82% share in 2023. The growth in the region is attributed to factors such as an enhanced regulatory landscape, an increasing number of clinical trials, a growing number of pharmaceutical companies, and the availability of skilled workers in the region.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definitions
    • 1.2.1. Type Segment
    • 1.2.2. Services Segment
    • 1.2.3. Category Segment
    • 1.2.4. Indication Segment
    • 1.2.5. Product Stage Segment
    • 1.2.6. Company Size Segment
    • 1.2.7. Indication Segment
    • 1.2.8. End Use Segment
  • 1.3. Information analysis
    • 1.3.1. Market formulation & data visualization
  • 1.4. Data validation & publishing
  • 1.5. Information Procurement
    • 1.5.1. Primary Research
  • 1.6. Information or Data Analysis
  • 1.7. Market Formulation & Validation
  • 1.8. Market Model
  • 1.9. Total Market: CAGR Calculation
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Snapshot
  • 2.3. Competitive Insights Landscape

Chapter 3. Regulatory Affairs Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook.
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Changing Regulatory Landscape
      • 3.2.1.2. Entry Of Companies into The Global Market
      • 3.2.1.3. Life Science Companies Focusing on Their Core Competencies
      • 3.2.1.4. Economic And Competitive Pressures
      • 3.2.1.5. Demand For the Faster Approval Process for Breakthrough Drugs and Devices
      • 3.2.1.6. Growth In Emerging Areas Such as Personalized Medicine, Biosimilars, And Orphan Drugs
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Risk Associated with Data Security
      • 3.2.2.2. Monitoring Issues and Lack of Standardization
  • 3.3. Regulatory Affairs Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
    • 3.3.2. PESTEL Analysis
    • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Regulatory Affairs Market: Services Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Global Regulatory Affairs Market Services Movement Analysis
  • 4.3. Global Regulatory Affairs Market Size & Trend Analysis, by Services, 2018 to 2030 (USD Billion)
  • 4.4. Regulatory Consulting
    • 4.4.1. Regulatory consulting market estimates and forecasts, 2018 - 2030 (USD Billion)
  • 4.5. Legal Representation
    • 4.5.1. Legal representation market estimates and forecasts, 2018 - 2030 (USD Billion)
  • 4.6. Regulatory Writing & Publishing
    • 4.6.1. Regulatory writing & publishing market estimates and forecasts, 2018 - 2030 (USD Billion)
    • 4.6.2. Writing
      • 4.6.2.1. Writing market estimates and forecasts, 2018 - 2030 (USD Billion)
    • 4.6.3. Publishing
      • 4.6.3.1. Publishing market estimates and forecasts, 2018 - 2030 (USD Billion)
  • 4.7. Product Registration & Clinical Trial Applications
    • 4.7.1. Product registration & clinical trial applications market estimates and forecasts, 2018 - 2030 (USD Billion)
  • 4.8. Other Services
    • 4.8.1. Other services market estimates and forecasts, 2018 - 2030 (USD Billion)

Chapter 5. Regulatory Affairs Market: Category Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Global Regulatory Affairs Market Category Movement Analysis
  • 5.3. Global Regulatory Affairs Market Size & Trend Analysis, by Category, 2018 to 2030 (USD Billion)
  • 5.4. Drugs
    • 5.4.1. Drugs market estimates and forecasts, 2018 - 2030 (USD Billion)
    • 5.4.2. Innovator
      • 5.4.2.1. Innovator market estimates and forecasts, 2018 - 2030 (USD Billion)
      • 5.4.2.2. Preclinical
        • 5.4.2.2.1. Preclinical market estimates and forecasts, 2018 - 2030 (USD Billion)
      • 5.4.2.3. Clinical
        • 5.4.2.3.1. Clinical market estimates and forecasts, 2018 - 2030 (USD Billion)
      • 5.4.2.4. Pre-Market Approval (PMA)
        • 5.4.2.4.1. Pre-Market Approval (PMA) market estimates and forecasts, 2018 - 2030 (USD Billion)
    • 5.4.3. Generics
      • 5.4.3.1. Generics market estimates and forecasts, 2018 - 2030 (USD Billion)
      • 5.4.3.2. Preclinical
        • 5.4.3.2.1. Preclinical market estimates and forecasts, 2018 - 2030 (USD Billion)
      • 5.4.3.3. Clinical
        • 5.4.3.3.1. Clinical market estimates and forecasts, 2018 - 2030 (USD Billion)
      • 5.4.3.4. Pre-Market Approval (PMA)
        • 5.4.3.4.1. Pre-Market Approval (PMA) market estimates and forecasts, 2018 - 2030 (USD Billion)
  • 5.5. Biologics
    • 5.5.1. Biologics market estimates and forecasts, 2018 - 2030 (USD Billion)
    • 5.5.2. Biotech
      • 5.5.2.1. Biotech market estimates and forecasts, 2018 - 2030 (USD Billion)
      • 5.5.2.2. Preclinical
        • 5.5.2.2.1. Preclinical market estimates and forecasts, 2018 - 2030 (USD Billion)
      • 5.5.2.3. Clinical
        • 5.5.2.3.1. Clinical market estimates and forecasts, 2018 - 2030 (USD Billion)
      • 5.5.2.4. Pre-Market Approval (PMA)
        • 5.5.2.4.1. Pre-Market Approval (PMA) market estimates and forecasts, 2018 - 2030 (USD Billion)
    • 5.5.3. ATMP
      • 5.5.3.1. ATMP market estimates and forecasts, 2018 - 2030 (USD Billion)
      • 5.5.3.2. Preclinical
        • 5.5.3.2.1. Preclinical market estimates and forecasts, 2018 - 2030 (USD Billion)
      • 5.5.3.3. Clinical
        • 5.5.3.3.1. Clinical market estimates and forecasts, 2018 - 2030 (USD Billion)
      • 5.5.3.4. Pre-Market Approval (PMA)
        • 5.5.3.4.1. Pre-Market Approval (PMA) market estimates and forecasts, 2018 - 2030 (USD Billion)
    • 5.5.4. Biosimilars
      • 5.5.4.1. Biosimilars market estimates and forecasts, 2018 - 2030 (USD Billion)
      • 5.5.4.2. Preclinical
        • 5.5.4.2.1. Preclinical market estimates and forecasts, 2018 - 2030 (USD Billion)
      • 5.5.4.3. Clinical
        • 5.5.4.3.1. Clinical market estimates and forecasts, 2018 - 2030 (USD Billion)
      • 5.5.4.4. Pre-Market Approval (PMA)
        • 5.5.4.4.1. Pre-Market Approval (PMA) market estimates and forecasts, 2018 - 2030 (USD Billion)
  • 5.6. Medical Devices
    • 5.6.1. Medical devices market estimates and forecasts, 2018 - 2030 (USD Billion)
    • 5.6.2. Diagnostics
      • 5.6.2.1. Diagnostics market estimates and forecasts, 2018 - 2030 (USD Billion)
      • 5.6.2.2. Preclinical
        • 5.6.2.2.1. Preclinical market estimates and forecasts, 2018 - 2030 (USD Billion)
      • 5.6.2.3. Clinical
        • 5.6.2.3.1. Clinical market estimates and forecasts, 2018 - 2030 (USD Billion)
      • 5.6.2.4. Pre-Market Approval (PMA)
        • 5.6.2.4.1. Pre-Market Approval (PMA) market estimates and forecasts, 2018 - 2030 (USD Billion)
    • 5.6.3. Therapeutics
      • 5.6.3.1. Therapeutics market estimates and forecasts, 2018 - 2030 (USD Billion)
      • 5.6.3.2. Preclinical
        • 5.6.3.2.1. Preclinical market estimates and forecasts, 2018 - 2030 (USD Billion)
      • 5.6.3.3. Clinical
        • 5.6.3.3.1. Clinical market estimates and forecasts, 2018 - 2030 (USD Billion)
      • 5.6.3.4. Pre-Market Approval (PMA)
        • 5.6.3.4.1. Pre-Market Approval (PMA) market estimates and forecasts, 2018 - 2030 (USD Billion)

Chapter 6. Regulatory Affairs Market: Indication Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Global Regulatory Affairs Market Indication Movement Analysis
  • 6.3. Global Regulatory Affairs Market Size & Trend Analysis, by Indication, 2018 to 2030 (USD Billion)
  • 6.4. Oncology
    • 6.4.1. Oncology market estimates and forecasts, 2018 - 2030 (USD Billion)
  • 6.5. Neurology
    • 6.5.1. Neurology market estimates and forecasts, 2018 - 2030 (USD Billion)
  • 6.6. Cardiology
    • 6.6.1. Cardiology market estimates and forecasts, 2018 - 2030 (USD Billion)
  • 6.7. Immunology
    • 6.7.1. Immunology market estimates and forecasts, 2018 - 2030 (USD Billion)
  • 6.8. Others
    • 6.8.1. Others market estimates and forecasts, 2018 - 2030 (USD Billion)

Chapter 7. Regulatory Affairs Market: Product Stage Estimates & Trend Analysis

  • 7.1. Segment Dashboard
  • 7.2. Global Regulatory Affairs Market Product Stage Movement Analysis
  • 7.3. Global Regulatory Affairs Market Size & Trend Analysis, by Product Stage, 2018 to 2030 (USD Billion)
  • 7.4. Preclinical
    • 7.4.1. Preclinical market estimates and forecasts, 2018 - 2030 (USD Billion)
  • 7.5. Clinical studies
    • 7.5.1. Clinical studies market estimates and forecasts, 2018 - 2030 (USD Billion)
  • 7.6. PMA
    • 7.6.1. PMA market estimates and forecasts, 2018 - 2030 (USD Billion)

Chapter 8. Regulatory Affairs Market: Type Estimates & Trend Analysis

  • 8.1. Segment Dashboard
  • 8.2. Global Regulatory Affairs Market Type Movement Analysis
  • 8.3. Global Regulatory Affairs Market Size & Trend Analysis, by Type, 2018 to 2030 (USD Billion)
  • 8.4. In-house
    • 8.4.1. In-house market estimates and forecasts, 2018 - 2030 (USD Billion)
  • 8.5. Outsourced
    • 8.5.1. Outsourced market estimates and forecasts, 2018 - 2030 (USD Billion)

Chapter 9. Regulatory Affairs Market: Company Size Estimates & Trend Analysis

  • 9.1. Segment Dashboard
  • 9.2. Global Regulatory Affairs Market Company Size Movement Analysis
  • 9.3. Global Regulatory Affairs Market Size & Trend Analysis, by Company Size, 2018 to 2030 (USD Billion)
  • 9.4. Small
    • 9.4.1. Small market estimates and forecasts, 2018 - 2030 (USD Billion)
  • 9.5. Medium
    • 9.5.1. Medium market estimates and forecasts, 2018 - 2030 (USD Billion)
  • 9.6. Large
    • 9.6.1. Large market estimates and forecasts, 2018 - 2030 (USD Billion)

Chapter 10. Regulatory Affairs Market: End Use Estimates & Trend Analysis

  • 10.1. Segment Dashboard
  • 10.2. Global Regulatory Affairs Market End Use Movement Analysis
  • 10.3. Global Regulatory Affairs Market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Billion)
  • 10.4. Medical Device Companies
    • 10.4.1. Medical device companies market estimates and forecasts, 2018 - 2030 (USD Billion)
  • 10.5. Pharmaceutical Companies
    • 10.5.1. Pharmaceutical companies market estimates and forecasts, 2018 - 2030 (USD Billion)
  • 10.6. Biotechnology Companies
    • 10.6.1. Biotechnology companies market estimates and forecasts, 2018 - 2030 (USD Billion)

Chapter 11. Regulatory Affairs Market: Regional Estimates & Trend Analysis

  • 11.1. Regional Market Share Analysis, 2023 & 2030
  • 11.2. Regional Market Dashboard
  • 11.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 11.4. North America
    • 11.4.1. North America Market Estimates and Forecasts 2018 - 2030 (USD Billion)
    • 11.4.2. U.S.
      • 11.4.2.1. Key country dynamics
      • 11.4.2.2. Competitive scenario
      • 11.4.2.3. U.S. market estimates and forecasts 2018 - 2030 (USD Billion)
    • 11.4.3. Canada
      • 11.4.3.1. Key country dynamics
      • 11.4.3.2. Competitive scenario
      • 11.4.3.3. Canada market estimates and forecasts 2018 - 2030 (USD Billion)
    • 11.4.4. Mexico
      • 11.4.4.1. Key country dynamics
      • 11.4.4.2. Competitive scenario
      • 11.4.4.3. Mexico market estimates and forecasts 2018 - 2030 (USD Billion)
  • 11.5. Europe
    • 11.5.1. Europe Market Estimates and Forecasts 2018 - 2030 (USD Billion)
    • 11.5.2. UK
      • 11.5.2.1. Key country dynamics
      • 11.5.2.2. Competitive scenario
      • 11.5.2.3. UK market estimates and forecasts 2018 - 2030 (USD Billion)
    • 11.5.3. Germany
      • 11.5.3.1. Key country dynamics
      • 11.5.3.2. Competitive scenario
      • 11.5.3.3. Germany market estimates and forecasts 2018 - 2030 (USD Billion)
    • 11.5.4. France
      • 11.5.4.1. Key country dynamics
      • 11.5.4.2. Competitive scenario
      • 11.5.4.3. France market estimates and forecasts 2018 - 2030 (USD Billion)
    • 11.5.5. Italy
      • 11.5.5.1. Key country dynamics
      • 11.5.5.2. Competitive scenario
      • 11.5.5.3. Italy market estimates and forecasts 2018 - 2030 (USD Billion)
    • 11.5.6. Spain
      • 11.5.6.1. Key country dynamics
      • 11.5.6.2. Competitive scenario
      • 11.5.6.3. Spain market estimates and forecasts 2018 - 2030 (USD Billion)
    • 11.5.7. Denmark
      • 11.5.7.1. Key country dynamics
      • 11.5.7.2. Competitive scenario
      • 11.5.7.3. Denmark market estimates and forecasts 2018 - 2030 (USD Billion)
    • 11.5.8. Norway
      • 11.5.8.1. Key country dynamics
      • 11.5.8.2. Competitive scenario
      • 11.5.8.3. Norway market estimates and forecasts 2018 - 2030 (USD Billion)
    • 11.5.9. Netherlands
      • 11.5.9.1. Key country dynamics
      • 11.5.9.2. Competitive scenario
      • 11.5.9.3. Netherlands market estimates and forecasts 2018 - 2030 (USD Billion)
    • 11.5.10. Switzerland
      • 11.5.10.1. Key country dynamics
      • 11.5.10.2. Competitive scenario
      • 11.5.10.3. Switzerland market estimates and forecasts 2018 - 2030 (USD Billion)
    • 11.5.11. Sweden
      • 11.5.11.1. Key country dynamics
      • 11.5.11.2. Competitive scenario
      • 11.5.11.3. Sweden market estimates and forecasts 2018 - 2030 (USD Billion)
  • 11.6. Asia Pacific
    • 11.6.1. Asia Pacific Market Estimates and Forecasts 2018 - 2030 (USD Billion)
    • 11.6.2. Japan
      • 11.6.2.1. Key country dynamics
      • 11.6.2.2. Competitive scenario
      • 11.6.2.3. Japan market estimates and forecasts 2018 - 2030 (USD Billion)
    • 11.6.3. China
      • 11.6.3.1. Key country dynamics
      • 11.6.3.2. Competitive scenario
      • 11.6.3.3. China market estimates and forecasts 2018 - 2030 (USD Billion)
    • 11.6.4. India
      • 11.6.4.1. Key country dynamics
      • 11.6.4.2. Competitive scenario
      • 11.6.4.3. India market estimates and forecasts 2018 - 2030 (USD Billion)
    • 11.6.5. Australia
      • 11.6.5.1. Key country dynamics
      • 11.6.5.2. Competitive scenario
      • 11.6.5.3. Australia market estimates and forecasts 2018 - 2030 (USD Billion)
    • 11.6.6. South Korea
      • 11.6.6.1. Key country dynamics
      • 11.6.6.2. Competitive scenario
      • 11.6.6.3. South Korea market estimates and forecasts 2018 - 2030 (USD Billion)
    • 11.6.7. Thailand
      • 11.6.7.1. Key country dynamics
      • 11.6.7.2. Competitive scenario
      • 11.6.7.3. Thailand market estimates and forecasts 2018 - 2030 (USD Billion)
    • 11.6.8. Indonesia
      • 11.6.8.1. Key country dynamics
      • 11.6.8.2. Competitive scenario
      • 11.6.8.3. Indonesia market estimates and forecasts 2018 - 2030 (USD Billion)
    • 11.6.9. Malaysia
      • 11.6.9.1. Key country dynamics
      • 11.6.9.2. Competitive scenario
      • 11.6.9.3. Malaysia market estimates and forecasts 2018 - 2030 (USD Billion)
    • 11.6.10. Singapore
      • 11.6.10.1. Key country dynamics
      • 11.6.10.2. Competitive scenario
      • 11.6.10.3. Singapore market estimates and forecasts 2018 - 2030 (USD Billion)
    • 11.6.11. Taiwan
      • 11.6.11.1. Key country dynamics
      • 11.6.11.2. Competitive scenario
      • 11.6.11.3. Taiwan market estimates and forecasts 2018 - 2030 (USD Billion)
  • 11.7. Latin America
    • 11.7.1. Latin America Market Estimates and Forecasts 2018 - 2030 (USD Billion)
    • 11.7.2. Brazil
      • 11.7.2.1. Key country dynamics
      • 11.7.2.2. Competitive scenario
      • 11.7.2.3. Brazil market estimates and forecasts 2018 - 2030 (USD Billion)
    • 11.7.3. Argentina
      • 11.7.3.1. Key country dynamics
      • 11.7.3.2. Competitive scenario
      • 11.7.3.3. Argentina market estimates and forecasts 2018 - 2030 (USD Billion)
    • 11.7.4. Colombia
      • 11.7.4.1. Key country dynamics
      • 11.7.4.2. Competitive scenario
      • 11.7.4.3. Colombia market estimates and forecasts 2018 - 2030 (USD Billion)
    • 11.7.5. Chile
      • 11.7.5.1. Key country dynamics
      • 11.7.5.2. Competitive scenario
      • 11.7.5.3. Chile market estimates and forecasts 2018 - 2030 (USD Billion)
  • 11.8. MEA
    • 11.8.1. MEA Market Estimates and Forecasts 2018 - 2030 (USD Billion)
    • 11.8.2. South Africa
      • 11.8.2.1. Key country dynamics
      • 11.8.2.2. Competitive scenario
      • 11.8.2.3. South Africa market estimates and forecasts 2018 - 2030 (USD Billion)
    • 11.8.3. Saudi Arabia
      • 11.8.3.1. Key country dynamics
      • 11.8.3.2. Competitive scenario
      • 11.8.3.3. Saudi Arabia market estimates and forecasts 2018 - 2030 (USD Billion)
    • 11.8.4. UAE
      • 11.8.4.1. Key country dynamics
      • 11.8.4.2. Competitive scenario
      • 11.8.4.3. UAE market estimates and forecasts 2018 - 2030 (USD Billion)
    • 11.8.5. Egypt
      • 11.8.5.1. Key country dynamics
      • 11.8.5.2. Competitive scenario
      • 11.8.5.3. Egypt market estimates and forecasts 2018 - 2030 (USD Billion)
    • 11.8.6. Israel
      • 11.8.6.1. Key country dynamics
      • 11.8.6.2. Competitive scenario
      • 11.8.6.3. Israel market estimates and forecasts 2018 - 2030 (USD Billion)
    • 11.8.7. Kuwait
      • 11.8.7.1. Key country dynamics
      • 11.8.7.2. Competitive scenario
      • 11.8.7.3. Israel market estimates and forecasts 2018 - 2030 (USD Billion)

Chapter 12. Competitive Landscape

  • 12.1. Company/Competition Categorization
  • 12.2. Strategy Mapping
  • 12.3. Company Market Position Analysis, 2023
  • 12.4. Company Profiles/Listing
    • 12.4.1. Accell Clinical Research, LLC
      • 12.4.1.1. Company overview
      • 12.4.1.2. Financial performance
      • 12.4.1.3. Product benchmarking
      • 12.4.1.4. Strategic initiatives
    • 12.4.2. Genpact
      • 12.4.2.1. Company overview
      • 12.4.2.2. Financial performance
      • 12.4.2.3. Product benchmarking
      • 12.4.2.4. Strategic initiatives
    • 12.4.3. Criterium, Inc.
      • 12.4.3.1. Company overview
      • 12.4.3.2. Financial performance
      • 12.4.3.3. Product benchmarking
      • 12.4.3.4. Strategic initiatives
    • 12.4.4. ICON plc
      • 12.4.4.1. Company overview
      • 12.4.4.2. Financial performance
      • 12.4.4.3. Product benchmarking
      • 12.4.4.4. Strategic initiatives
    • 12.4.5. iuvo BioScience, llc.
      • 12.4.5.1. Company overview
      • 12.4.5.2. Financial performance
      • 12.4.5.3. Product benchmarking
      • 12.4.5.4. Strategic initiatives
    • 12.4.6. WuXi AppTec
      • 12.4.6.1. Company overview
      • 12.4.6.2. Financial performance
      • 12.4.6.3. Product benchmarking
      • 12.4.6.4. Strategic initiatives
    • 12.4.7. Medpace
      • 12.4.7.1. Company overview
      • 12.4.7.2. Financial performance
      • 12.4.7.3. Product benchmarking
      • 12.4.7.4. Strategic initiatives
    • 12.4.8. Charles River Laboratories
      • 12.4.8.1. Company overview
      • 12.4.8.2. Financial performance
      • 12.4.8.3. Product benchmarking
      • 12.4.8.4. Strategic initiatives
    • 12.4.9. Laboratory Corporation of America Holdings
      • 12.4.9.1. Company overview
      • 12.4.9.2. Financial performance
      • 12.4.9.3. Product benchmarking
      • 12.4.9.4. Strategic initiatives
    • 12.4.10. Parexel International (MA) Corporation
      • 12.4.10.1. Company overview
      • 12.4.10.2. Financial performance
      • 12.4.10.3. Product benchmarking
      • 12.4.10.4. Strategic initiatives
    • 12.4.11. Freyr
      • 12.4.11.1. Company overview
      • 12.4.11.2. Financial performance
      • 12.4.11.3. Product benchmarking
      • 12.4.11.4. Strategic initiatives
    • 12.4.12. PHARMALEX GMBH
      • 12.4.12.1. Company overview
      • 12.4.12.2. Financial performance
      • 12.4.12.3. Product benchmarking
      • 12.4.12.4. Strategic initiatives
    • 12.4.13. SSI Strategy LLC
      • 12.4.13.1. Company overview
      • 12.4.13.2. Financial performance
      • 12.4.13.3. Product benchmarking
      • 12.4.13.4. Strategic initiatives
    • 12.4.14. Pharmexon
      • 12.4.14.1. Company overview
      • 12.4.14.2. Financial performance
      • 12.4.14.3. Product benchmarking
      • 12.4.14.4. Strategic initiatives
    • 12.4.15. Qvigilance
      • 12.4.15.1. Company overview
      • 12.4.15.2. Financial performance
      • 12.4.15.3. Product benchmarking
      • 12.4.15.4. Strategic initiatives
    • 12.4.16. BlueReg
      • 12.4.16.1. Company overview
      • 12.4.16.2. Financial performance
      • 12.4.16.3. Product benchmarking
      • 12.4.16.4. Strategic initiatives
    • 12.4.17. Cambridge Regulatory Services
      • 12.4.17.1. Company overview
      • 12.4.17.2. Financial performance
      • 12.4.17.3. Product benchmarking
      • 12.4.17.4. Strategic initiatives
    • 12.4.18. VCLS
      • 12.4.18.1. Company overview
      • 12.4.18.2. Financial performance
      • 12.4.18.3. Product benchmarking
      • 12.4.18.4. Strategic initiatives
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제